Preparation and application of patient-derived xenograft mice model of colorectal cancer

Document Type : Original Article

Authors

1 Department of Colorectal and Anal Surgery, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, 030013, Taiyuan, Shanxi, China

2 Laboratory Animal Center, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, 030013, Taiyuan, Shanxi, China

3 Department of Pathology, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, 030013, Taiyuan, Shanxi, China

Abstract

Objective(s): Patient-derived xenograft (PDX) model becomes a more and more important tool for tumor research. This study aimed to establish a colorectal cancer PDX model and verify its applicability.
Materials and Methods: Fresh human colorectal cancer tissue was surgically removed and subcutaneously inoculated into immunodeficient mice to establish the PDX model. Hematoxylin and eosin (HE) staining and immunohistochemical staining were used to evaluate the model. The successful PDX model was selected to study the efficacy of capecitabine in treating colorectal cancer. 
Results: HE staining showed that the PDX mice model of colorectal cancer could preserve the histological characteristics of the primary tumor. Immunohistochemistry staining showed α-fetoprotein (AFP), carcinoembryonic antigen (CEA), and E-cadherin were strongly positively expressed in primary human and PDX tumor tissues, with a high degree of similarity. Capecitabine significantly inhibited PDX tumor growth and reduced the expression of AFP and CEA proteins in the tumor tissues (all Ps<0.05). 
Conclusion: We successfully established a colorectal cancer PDX model, and the PDX model could retain the histological and biological characteristics of the primary tumor. Using this PDX model, we revealed that capecitabine at a dose of 300–400 mg/kg can effectively treat colorectal cancer, and no significant difference in toxicity was found among different dose groups. The current work provides a feasible framework for establishing and validating the PDX tumor model to better facilitate the evaluation of drug efficacy and safety.

Keywords

References

1. Bure IV, Nemtsova MV, Zaletaev DV. Roles of E-cadherin and noncoding RNAs in the epithelial-mesenchymal transition and progression in gastric cancer. Int J Mol Sci 2019; 20: 2870-2892.
2. Hu Y, Wang JL, Tao HT, Wu BS, Sun J, Cheng Y, et al. Expression and significance of TSGF, CEA and AFP in patients before and after radical surgery for colon cancer. Asian Pac J Cancer Prev 2013; 14:3877-3880.
3. Piawah S, Venook AP. Targeted therapy for colorectal cancer metastases: A review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer. Cancer 2019; 125:4139-4147.
4. Heinimann K. [Hereditary Colorectal Cancer: Clinics, Diagnostics and Management]. Ther Umsch 2018; 75:601-606.
5. Sherman SK, Lange JJ, Dahdaleh FS, Rajeev R, Gamblin TC, Polite BN, et al. Cost-effectiveness of maintenance capecitabine and bevacizumab for metastatic colorectal cancer. JAMA Oncol 2019; 5:236-242.
6. Gawin M, Kurczyk A, Niemiec J, Stanek-Widera A, Grela-Wojewoda A, Adamczyk A, et al. Intra-tumor heterogeneity revealed by mass spectrometry imaging is associated with the prognosis of breast cancer. Cancers (Basel) 2021; 13:4349.
7. Du XW, Li G, Liu J, Zhang CY, Liu Q, Wang H, et al. Comprehensive analysis of the cancer driver genes in breast cancer demonstrates their roles in cancer prognosis and tumor microenvironment. World J Surg Oncol 2021; 19:273.
8. Okada S, Vaeteewoottacharn K, Kariya R. Application of Highly Immunocompromised Mice for the Establishment of Patient-Derived Xenograft (PDX) Models. Cells 2019; 8:889.
9. Hidalgo M, Amant F, Biankin AV, Budinska E, Byrne AT, Caldas C, et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov 2014; 4:998-1013.
10. Rivera M, Fichtner I, Wulf-Goldenberg A, Sers C, Merk J, Patone G, et al. Patient-derived xenograft (PDX) models of colorectal carcinoma (CRC) as a platform for chemosensitivity and biomarker analysis in personalized medicine. Neoplasia 2021; 23:21-35.
11. Jung J, Seol HS, Chang S. The generation and application of patient-derived xenograft model for cancer research. Cancer Res Treat 2018; 50:1-10.
12. Burgenske DM, Monsma DJ, MacKeigan JP. Patient-derived xenograft models of colorectal cancer: procedures for engraftment and propagation. Methods Mol Biol 2018; 1765:307-314.
13. Sun W. Evolution of capecitabine dosing in colorectal cancer. Clin Colorectal Cancer 2010; 9:31-39.
14. Meehan TF. Know thy PDX model. Cancer Res 2019; 79:4324-4325.
15. Yoshida GJ. Applications of patient-derived tumor xenograft models and tumor organoids. J Hematol Oncol 2020; 13:4-19.
16. Kelly C, Cassidy J. Capecitabine in the treatment of colorectal cancer. Expert Rev Anticancer Ther 2007; 7:803-810.
17. Stewart T, Pavlakis N, Ward M. Cardiotoxicity with 5-fluorouracil and capecitabine: More than just vasospastic angina. Intern Med J 2010; 40:303-307.
18. Stathopoulos GP, Koutantos J, Lazaki H, Rigatos SK, Stathopoulos J, Deliconstantinos G. Capecitabine (Xeloda) as monotherapy in advanced breast and colorectal cancer: Effectiveness and side-effects. Anticancer Res 2007; 27:1653-1656.
19. Kwakman JJM, Simkens LHJ, van Rooijen JM, van de Wouw AJ, Ten Tije AJ, Creemers GJM, et al. Randomized phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer Group. Ann Oncol 2017; 28:1288-1293.
20. Hirsch BR, Zafar SY. Capecitabine in the management of colorectal cancer. Cancer Manag Res 2011; 3:79-89.
21. Maletzki C, Bock S, Fruh P, Macius K, Witt A, Prall F, et al. NSG mice as hosts for oncological precision medicine. Lab Invest 2020; 100:27-37.
22. Yang M, Fang X, Li J, Xu D, Xiao Q, Yu S, et al. Afatinib treatment for her-2 amplified metastatic colorectal cancer based on patient-derived xenograft models and next generation sequencing. Cancer Biol Ther 2019; 20:391-396.
23. Jin K, Lan H, Xie B, He K, Xu Z, Li G, et al. Antitumor effects of FP3 in combination with capecitabine on PDTT xenograft models of primary colon carcinoma and related lymphatic and hepatic metastases. Cancer Biol Ther 2012; 13:737-744.
24. Ren F, Weng W, Zhang Q, Tan C, Xu M, Zhang M, et al. Clinicopathological features and prognosis of AFP-producing colorectal cancer: a single-center analysis of 20 cases. Cancer Manag Res 2019; 11:4557-4567.
25. Jelski W, Mroczko B. Biochemical markers of colorectal cancer - present and future. Cancer Manag Res 2020; 12:4789-4797.
26. Bosma MJ. B and T cell leakiness in the scid mouse mutant. Immunodefic Rev 1992; 3:261-276.
27. Wang W, Zhang Y, Peng Y, Jin KZ, Li YL, Liang Y, et al. A Ki-67 index to predict treatment response to the capecitabine/temozolomide regimen in neuroendocrine neoplasms: A retrospective multicenter study. Neuroendocrinology 2021; 111:752-763.
28. Li C, Ci Y, Liu X, Chen C, Liu C, Li X, et al. Inositol hexakisphosphate and inositol enhance the inhibition of colorectal cancer growth and liver metastasis by capecitabine in a mouse model. Nutr Cancer 2020:1-9.
Iranian Journal of Basic Medical Sciences
Volume 26, Issue 2
February 2023
Pages 248-254

Files

Share

How to cite

Statistics